Treatment of WHO 1: GnRH or gonadotropins?

The administration of gonadotropin releasing hormone (GnRH) given in a very particular episodic way has established itself as the prime therapy for induction of ovulation in hypogonadotropic amenorrhea of supra-pituitary origin (WHO 1). The goal of pulsatile GnRH in ovulation induction is to obtain endogenous pituitary gonadotropin secretion that results in a preferably mono-ovulatory response of the ovaries. So a logical question is why not administer the gonadotropins straight away? In view of current highly advocated evidence-based medical practice lies this relatively straightforward question wide open because the literature provides absolutely insufficient data.